Myo-Inositol for Gestational Diabetes during pregnancy
Gestational diabetes is a unique type of diabetes. It develops only during pregnancy and, as with diabetes, blood glucose ("blood sugar") levels are abnormally high and can become dangerous to the pregnant women as well as to the baby. It developed as the body during the jormonal changes in the pregancy could not produce enough insulin, the hormone to control blood glucose levels and using the blood glucose for energy in each cell effectively, a condition called insulin resistance. Gestational diabetes is usually diagnosed during late pregnancy in an easy test after the usual and easy glucose test between weeks 24 and 28 of the pregnancy (1).
Treating gestational diabetes can be important and help both you and your baby stay healthy avoiding macrosomia, hypoglycemia, respiratory distress syndrome or even death. You can protect your baby and yourself by taking action right away to control your blood glucose levels by nutrition changes, but even better by adding the unique combination of Myo - Inositol and Folic Acid (product called INOFOLIC®) as preventive method.
"Myo-Inositol improves insulin resistance in patients with gestational diabetes." concluded the study publication of published in Diabet. Med. 28, 972–975 (2011). 69 patients, "24 in the study group and 45 in the control group were evaluated. ...Insulin resistance decreased in both groups: 50% in the study group vs. 29% in the control group". This was due to nutritional changes, but the "decline in the group using myo-Inositol was significantly greater than that in the control group (P = 0.0001)" (2).
But why using myo-Inositol only if you were diagnosed, doesn't it work preventively? In another study was monitored two study groups with similar population of women suffering PCOS. "A total of 98 pregnancies in PCOS women obtained in a 3-year period, either with myo-inositol (n. 54), or with metformin (n. 44)." In the myo-inositol group only 17.4% (8 cases out of 46) developed Gestational Diabetes, while in the control group 54% of women developed Gestational Diabetes (20 women out of 37). "The difference of Gestational Diabetes occurrence comparing the groups was highly significant (p = 0.001), also after adjustment for covariates (age, BMI, percentage of nulliparous, parents with diabetes)." In this clinical study the daily dose of 4 g myo - Inositol and 400 mcg Folic Acid was used (product called INOFOLIC® twice daily). The study concluded: "Myo-inositol may prevent gestational diabetes in PCOS women". And by the way: "...no side effect was reported by the patients during myo-inositol treatment" (3).
But what about high risk patient e.g. in pregnant women with a family history of type 2 diabetes? "Incidence of Gestational Diabetes was significantly reduced in the myo-Inositol group compared with the placebo group: 6 vs. 15.3%, respectively (P = 0.04). In the myo-Inositol group, a reduction of Gestational Diabetes risk occurrence was highlighted (odds ratio 0.35). A statistically significant reduction of fetal macrosomia in the myo-Inositol group was also highlighted together with a significant reduction in mean fetal weight at delivery." In a 2-year, prospective, randomized, open-label, placebo-controlled study pregnant women with a parent diagnosed type 2 diabetes were analysed. From the end of the first trimester they were treated with 2 g myo-inositol plus 400 mg folic acid twice a day (n = 110, product called INOFOLIC®) or with 400 mg folic acid twice a day in the placebo group (n = 110).
The main outcome measure was the incidence of Gestational Diabetes in both groups. Secondary outcome measures were as follows: the incidence of fetal macrosomia (4,000 g), gestational hypertension, preterm delivery, caesarean section, shoulder dystocia, neonatal hypoglycemia, and neonatal distress respiratory syndrome. Gestational Diabetes diagnosis was performed according to the International Association of Diabetes in Pregnancy Study Group (IADPSG) recommendations (4). Insulin resistance was calculated by homeo- stasis model assessment of insulin resistance (HOMA-IR)(5).